Navigation Links
Potential New Cancer Gene Identified

A Johns Hopkins University research team has discovered a new family of genes that contributes to the process of malignancy, shedding new light on the abnormalities that give rise to the aggressive childhood cancer, Burkitt's lymphoma - as well as lymphoma, leukemia, prostate, ovarian, lung, and breast cancer.

Characterized by rapidly growing abdominal tumors, Burkitt's lymphoma is one of the three major types of pediatric non-Hodgkin's lymphomas, representing 40% of that group. According to the American Cancer Society, aproximately 57,000 children are diagnosed with non-Hodgkin's lymphoma per year in the United States, representing about 6% of cancers in children. While aggressive, Burkitt's lymphoma responds well to chemotherapy, and has a 90% survival rate if the tumor has not spread beyond the abdomen.

Scientists have long known that the "myc" family of genes plays a prominent role in tumor formation, also called neoplastic transformation. The Hopkins team, focusing on c-myc, found that another gene called the HMG-I/Y gene is a key genetic "target" necessary for Myc-mediated transformation.

When the expression of this target gene in Burkitt's lymphoma cell lines was blocked, the cancer cells revert back to normal-appearing cells. This could point the way to new therapies for one of the most aggressive childhood cancers, as well as other cancers associated with increases in the HMG-I/Y gene according to the Johns Hopkin's research team.
'"/>




Page: 1

Related medicine news :

1. Lack of Smell And Its Potential Risks
2. New Blood Thinner Pill - First Potential Alternative to Warfarin in 50 years
3. The Potential Of Cadaver Transplantation Programme In India
4. Another Potential Of Stem Cells Discovered: Used For Growing Cartilage
5. Yoga Guru Ramdev Invited to Tap Ayurveda Potential by Jharkhand Govt
6. A Protein In Yoghurt Has The Potential To Fight E. coli
7. Gold Therapy- A Potential Treatment For Autoimmune Diseases
8. Whirlpool Bath Tubs Contain Potentially Lethal Bacterial Strains
9. Potential Benefits Of New Nanotechnology
10. Hormone Can Foretell Presence Of Potentially Fatal Pulmonary Hypertension
11. UC Researchers Find Potential Drug Target For SARS
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Potential New Cancer Gene Identified

(Date:5/17/2008)... safe-limit price as guide for avoiding exposure ... Those inexpensive earrings you bought from a hip ...t bad for your ears and skin. , A new report fi... $50 by local San Francisco stores and artists con...lobes and repeated exposure can make treatment dif...
(Date:5/16/2008)...JoAnne,s Bed & Back; Merger Sets Up Healthy B...ail Chain, LORTON, Va., May 16 /PRNewswire/ -- He... home and workplace back wellness created an,ergon...ts of its rival,JoAnne,s Bed & Back. Healthy Back...evenues of $40million. JoAnne,s 16 mid-Atlantic st...
(Date:5/16/2008)...e in serum parathyroid hormone readings, study say... Low levels of vitamin D and high levels of a horm...e the risk of depression in older adults, accordin...d in the May issue of Archives of General Psychia... that vitamin D, depression and other psychiatric ...
(Date:5/16/2008)...ize the Importance of Oral and Overall Health, HA...tal insurer United,Concordia Dental is celebrating...l Health America and the British Dental Health Fou...o overall health. Beginning May 18,this year,s ev...t time,making it the largest independent internat...
Breaking Medicine News(10 mins):Health News:Cheaper Earrings More Likely to Contain Nickel 2Health News:Cheaper Earrings More Likely to Contain Nickel 3Health News:The Back Wars Come to a Close 2Health News:Low Vitamin D Tied to Depression in Older Adults 2Health News:United Concordia Dental Celebrates National Smile Month 2
...were to be serious accidents or injury due to some...in the treatment of such persons in the emergency ...are undertaken in the intensive care are varied an...death of the patient. Scientists are now working ...
...rapy, which is touted as the best and latest in ca...y's Mater Hospital Radiotherpahy Department.// It..., and is set to improve results with fewer side ef...of its kind in the southern hemisphere, bringing t...
...ersy sparked off by a Holyrood committee’s call fo... of patients with hepatitis C through NHS treatmen...new evidence showing lack of resources was the rea...tients infected with the fatal virus, the Health C...
...people in Ratlam in Madhya Pradesh fell ill after ...ident in five days in the district, police said Th... to Ratlam district hospital, the rest were discha...spital spokesman said. Earlier, 35 people had fal...
Other Medicine News:Health News:Guidelines For Treating Severely Injured Patients On The Anvil 2
(Date:5/16/2008)...s., May 16 /- BioVex Inc, a biotechno... oncology and infectious,disease, announced today ...rom its Phase II clinical trial of OncoVEX GM-CSF ...t the American Society of Clinical Oncology,(ASCO)...ry of the abstract,which describes the data as of ...
(Date:5/16/2008)...as Potential Biomarkers -- for Lung Cancer Diagnos... With Cancer of Unknown Primary ...ify Cancer Types With High Sensitivity and, Spec...tment of Cancer Results of microRNA Signature to ...uracy Exceeding 90% and Specificity of 99%, REHOV...
(Date:5/16/2008)...onstrates Statistically Significant Reductions in ...ons, - Abstract to be published in 2008 Proceeding... Clinical Oncology, SAN DIEGO, May 16 /PRNews...(Amex: ANX ) announced today that, in a registrat...strated a statistically significant reduction,in g...
(Date:5/15/2008)...zerland, May 15 /- Patients with brea...ommon cancers, can expect,further treatment advanc...(trastuzumab) following new data that is being pre...cology (ASCO) annual meeting in Chicago at,the end... the meeting which,is the premier event for cancer...
Breaking Medicine Technology:BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 2BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 3Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 3Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 4Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 5Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 6ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 2ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 3ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 4ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 5New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 2New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 3New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 4New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 5New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 6Corgenix Announces FDA Clearance for IgG Anti AtherOx 28R 29 Test Kit 4509 1Corgenix Announces FDA Clearance for IgG Anti AtherOx 28R 29 Test Kit 4509 2Corgenix Announces FDA Clearance for IgG Anti AtherOx 28R 29 Test Kit 4509 3Millennium Announces VELCADE 28R 29 28Bortezomib 29 for Injection First Quarter 2008 U S Net Sales 4507 1Millennium Announces VELCADE 28R 29 28Bortezomib 29 for Injection First Quarter 2008 U S Net Sales 4507 2Millennium Announces VELCADE 28R 29 28Bortezomib 29 for Injection First Quarter 2008 U S Net Sales 4507 3Millennium Announces VELCADE 28R 29 28Bortezomib 29 for Injection First Quarter 2008 U S Net Sales 4507 4Millennium Announces VELCADE 28R 29 28Bortezomib 29 for Injection First Quarter 2008 U S Net Sales 4507 5Millennium Announces VELCADE 28R 29 28Bortezomib 29 for Injection First Quarter 2008 U S Net Sales 4507 6Millennium Announces VELCADE 28R 29 28Bortezomib 29 for Injection First Quarter 2008 U S Net Sales 4507 7Method to deliver molecules within embryonic stem cells improves differentiation 4505 1Method to deliver molecules within embryonic stem cells improves differentiation 4505 2Method to deliver molecules within embryonic stem cells improves differentiation 4505 3PEMCOs Super Long Coffee Order Contest Taps First Winners 16440 1PEMCOs Super Long Coffee Order Contest Taps First Winners 16440 2
...; MENLO PARK, Calif.--(BUSINESS WIRE)--May,21, 200...XSP) notes,the publication of new clinical data re...R) (homoharringtonine). The paper "Targeted,therap...leukemias",by researchers Simona Soverini and coll...ologica Volume 92, pages 401-404) offers,insight i...
...E)--May 21, 2007 - Results from a new,study, prese...W),conference, showed that more than 99 percent of...ection who were treated,successfully with PEGASYS(... up to seven years later - validating the use of,t...ing to study,authors. Currently, the best indicato...
Other Medicine Technology:Independent Publication Confirms Growing Therapeutic Challenge of,T315I Mutation in Patients with CML, Notes ChemGenex 2Independent Publication Confirms Growing Therapeutic Challenge of,T315I Mutation in Patients with CML, Notes ChemGenex 3Pegasys Study Authors Conclude that Patients Successfully Treated,for Hepatitis C Can be Considered ''Cured'' 2Pegasys Study Authors Conclude that Patients Successfully Treated,for Hepatitis C Can be Considered ''Cured'' 3Pegasys Study Authors Conclude that Patients Successfully Treated,for Hepatitis C Can be Considered ''Cured'' 4Pegasys Study Authors Conclude that Patients Successfully Treated,for Hepatitis C Can be Considered ''Cured'' 5Pegasys Study Authors Conclude that Patients Successfully Treated,for Hepatitis C Can be Considered ''Cured'' 6
... Transport beds feature folding head end and foot ... With the head end and foot end deck panels folded...ximately 67". This compact length makes storage, d...is feature is not available on Model 4748B, Basic ...
.... Patient dignity. A single solution., ,Hill-Rom ...d to provide added safety where its needed. Its lo...the caregiver and patient from injury, while impro... other TotalCare® beds, but its different the...
...able Prefilled 28%-100% FIO 2 1000ML 0.45% Sodium... unmatched performance and ease of use. You can ob...le from 28% to 100% FIO 2 . We offer a wide select...P; 0.45% sodium chloride inhalation, USP; and 0.9%...
...led 750ML Sterile H 2 O W/O Adapter., ,Filled...er systems feature a dual-purpose reservoir with a...r secure attachment of a humidifier adapter. The o...ate from reaching oxygen delivery tubing. An audib...
Medicine Products: